Join our Newsletter
Browse by Category
-
Most Read this Week
- Anti-malaria groups warn of growing insecticide resistance
- Global Fund board meets in Geneva
- Theraclone Sciences reports positive phase 1 trial results for influenza A antibody
- Maryland proposes additional pertussis, chicken pox booster requirement
- Montana county fights worst ever pertussis outbreak
Tags
Africa AIDS anthrax Australia California Canada Cancer Centers for Disease Control chicken pox China cholera Dengue fever Detection technology Ebola Emergency preparedness H1N1 H5N1 Haiti hepatits Human papillomavirus immunization India Infectious disease Influenza Malaria Maryland Massachusetts Measles Medical Countermeasures meningitis MRSA Mumps New York Pertussis pneumococcal disease pneumonia polio Preparedness research rotavirus Shingles Tuberculosis vaccine development whooping cough World Health Organization
Author Archives: Nick Rees
CDC expanding disease detection center program to protect against emerging diseases
“Global health security is only as strong as the weakest link,” Ray Arthur, Associate Director for Global Health at CDC National Center for Infectious Diseases, said as part of a presentation on the CDC’s Global Disease Protection Plan at last week’s 2010 Read More »
Filed in Vaccine Development
Comments Off
Pig virus DNA found in Merck’s Rotateq vaccine
The U.S. Food and Drug Administration reported May 6 that fragments of two types of pig viruses were found in Merck & Co.’s Rotateq vaccine. Read More »
Filed in FDA
Comments Off
Aradigm gets FDA approval for Cystic drug fibrosis clinical trial
Aradigm Corporation announced that it has received clearance from the U.S. Food and Drug Administration for its inhaled liposomal ciprofloxacin Investigational New Drug application. Read More »
Filed in Vaccine Development
Comments Off
Child vaccine refusals on the rise in the U.S.
More U.S. parents are refusing or delaying vaccinations for their children, a study presented May 4 at the annual meeting of the Pediatric Academic Societies in Vancouver has revealed. Read More »
Filed in News
Comments Off
Advaxis advances clinical development of prostate cancer vaccine
Advaxis, Inc., a biotechnology company that develops proprietary, live, attenuated Listeria monocytogenes immunotherapeutics that deliver engineered tumor antigens, which are used to fight cancer, announced that it is advancing the clinical development of Read More »
Filed in Vaccine Development
Comments Off